<DOC>
	<DOCNO>NCT02295969</DOCNO>
	<brief_summary>Safety tolerability ORALAIR child 5 9 year age first 30 day treatment .</brief_summary>
	<brief_title>Observational Study OralairÂ® Children 5-9 Years With Grass-pollen-induced Allergic Rhinitis With/Without Conjunctivitis</brief_title>
	<detailed_description>The purpose study describe safety tolerability ORALAIR tablets child 5 9 year age grass-pollen-induced allergic rhinitis without conjunctivitis . Patients follow safety tolerability first 30 treatment day .</detailed_description>
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<mesh_term>Conjunctivitis</mesh_term>
	<criteria>Allergen immunotherapy naive male female outpatient age 5 9 year ( inclusive ) prescribe ORALAIR . Patients already participate clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>9 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Rhinitis</keyword>
	<keyword>Conjunctivitis</keyword>
	<keyword>Grass pollen</keyword>
	<keyword>Sublingual tablet</keyword>
	<keyword>Allergen immunotherapy</keyword>
	<keyword>Safety</keyword>
</DOC>